S. 1954 119th Congress
Biosimilar Red Tape Elimination Act
Latest action, Jul 27, 2026: Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
5 cosponsors
Sponsored by Mike Lee (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
3 D · 2 R
- Democrat
- Republican
- Independent
Referred to: Senate: Health, Education, Labor, and Pensions Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
6 reports
6 reports
ASSOCIATION OF ACCESSIBLE MEDICINES
MEHLMAN CONSULTING, INC.
6 reports
6 reports
THE CAMPAIGN FOR SUSTAINABLE RX PRICING
MEHLMAN CONSULTING, INC.
6 reports
5 reports
ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA)
FIERCE GOVERNMENT RELATIONS
5 reports
BCBSM INC
5 reports
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)
WHITMER & WORRALL, LLC
5 reports
5 reports
All 25 of 37 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | 6 | $23.7M | Q4 2025 | Q3 2026 | yes | |
| AMGEN INC | 6 | $17.9M | Q4 2025 | Q3 2026 | yes | |
| ASSOCIATION FOR CLINICAL ONCOLOGY | 6 | $1.6M | Q4 2025 | Q3 2026 | yes | |
| ASSOCIATION OF ACCESSIBLE MEDICINES | MEHLMAN CONSULTING, INC. | 6 | $360K | Q4 2025 | Q3 2026 | yes |
| JOHNSON & JOHNSON SERVICES INC | 6 | $12.2M | Q4 2025 | Q3 2026 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 6 | $51.6M | Q4 2025 | Q3 2026 | yes | |
| THE CAMPAIGN FOR SUSTAINABLE RX PRICING | MEHLMAN CONSULTING, INC. | 6 | $540K | Q4 2025 | Q3 2026 | yes |
| AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 5 | $1.2M | Q4 2025 | Q3 2026 | yes | |
| ASSOCIATION FOR ACCESSIBLE MEDICINES | 5 | $4.2M | Q4 2025 | Q2 2026 | yes | |
| ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA) | FIERCE GOVERNMENT RELATIONS | 5 | $300K | Q4 2025 | Q3 2026 | yes |
| BCBSM INC | 5 | $148K | Q4 2025 | Q3 2026 | yes | |
| BLUE CROSS AND BLUE SHIELD ASSOCIATION | 5 | $6.3M | Q4 2025 | Q3 2026 | yes | |
| BLUE CROSS AND BLUE SHIELD OF FLORIDA INC | 5 | $480K | Q4 2025 | Q3 2026 | yes | |
| CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) | WHITMER & WORRALL, LLC | 5 | $250K | Q4 2025 | Q2 2026 | yes |
| GSK (FKA GLAXOSMITHKLINE INC.) | 5 | $6.4M | Q4 2025 | Q3 2026 | yes | |
| GUIDEWELL MUTUAL HOLDING CORPORATION | 5 | $30K | Q4 2025 | Q3 2026 | yes | |
| PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC | COVINGTON & BURLING LLP | 5 | $0 | Q2 2025 | Q3 2026 | yes |
| THE BIOSIMILARS FORUM | THORN RUN PARTNERS | 5 | $500K | Q4 2025 | Q3 2026 | yes |
| VIZIENT INC | 5 | $1.6M | Q4 2025 | Q3 2026 | yes | |
| AMERICAN COLLEGE OF RHEUMATOLOGY | 4 | $310K | Q4 2025 | Q3 2026 | yes | |
| CAMBIA HEALTH SOLUTIONS | 4 | $2.6M | Q4 2025 | Q3 2026 | yes | |
| FRESENIUS KABI USA LLC | 4 | $2.0M | Q4 2025 | Q3 2026 | yes | |
| 60 PLUS ASSOCIATION | 3 | $0 | Q4 2025 | Q3 2025 | — | |
| BLUE CROSS AND BLUE SHIELD OF KANSAS INC | 3 | $30K | Q1 2026 | Q3 2026 | yes | |
| KAISER FOUNDATION HEALTH PLAN INC | 3 | $4.0M | Q1 2026 | Q3 2026 | yes |